Health-related quality of life in patients with lung cancer: Validation of the Mexican-Spanish version and association with prognosis of the EORTC QLQ-LC13 questionnaire

Lung Cancer ◽  
2012 ◽  
Vol 77 (1) ◽  
pp. 205-211 ◽  
Author(s):  
Óscar Arrieta ◽  
Carolina Núñez-Valencia ◽  
Leonardo Reynoso-Erazo ◽  
Salvador Alvarado ◽  
Diana Flores-Estrada ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Spanish Version ◽  
Health Related Quality ◽  
Mexican Spanish ◽  
Related Quality ◽  
Health Related ◽  
Eortc Qlq

Validation of the Mexican Spanish Version of the EORTC QLQ-H&N35 Instrument to Measure Health-related Quality of Life in Patients with Head and Neck Cancers

2012 ◽  
Vol 20 (5) ◽  
pp. 1417-1426 ◽  
Author(s):  
José F. Carrillo ◽  
Miguel Ángel Ortiz-Toledo ◽  
Zarahi Salido-Noriega ◽  
Norma Berenice Romero-Ventura ◽  
Francisco J. Ochoa-Carrillo ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Head And Neck ◽  
Head And Neck Cancers ◽  
Spanish Version ◽  
Health Related Quality ◽  
Mexican Spanish ◽  
Related Quality ◽  
Health Related ◽  
Eortc Qlq

Validation of the Mexican-Spanish version of the EORTC QLQ-C15-PAL questionnaire for the evaluation of health-related quality of life in patients on palliative care

2010 ◽  
Vol 20 (8) ◽  
pp. 889-896 ◽  
Author(s):  
Yolanda Suárez-del-Real ◽  
Silvia Allende-Pérez ◽  
Araceli Alférez-Mancera ◽  
Rosa Bertha Rodríguez ◽  
Silvia Jiménez-Toxtle ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Palliative Care ◽  
Spanish Version ◽  
Health Related Quality ◽  
Mexican Spanish ◽  
Related Quality ◽  
Health Related ◽  
Eortc Qlq

Does change in health-related quality of life (HRQoL) score predict survival? Analysis of a lung cancer RCT.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 7607-7607
Author(s):  
Divine Ewane Ediebah ◽  
Corneel Coens ◽  
Efstathios Zikos ◽  
Chantal Quinten ◽  
Jolie Ringash ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Performance Status ◽  
Health Related Quality ◽  
Related Quality ◽  
Eortc Qlq C30 ◽  
Health Related ◽  
Eortc Qlq ◽  
Over Time

7607 Background: Over 60 cancer clinical trials have shown that baseline health-related quality of life (HRQoL) scores are prognostic for patient survival. Few studies have investigated the added value of change in HRQoL scores. Our aim was to investigate if change in HRQoL scores from baseline over time is also associated with survival. Methods: We analyzed data from an EORTC 3-arm randomized clinical trial (RCT) in advanced non-small-cell lung cancer (NSCLC) patients, comparing gemcitabine+cisplatin, versus paclitaxel+gemcitabine, versus standard arm paclitaxel+cisplatin. HRQoL was measured in 394 patients using the EORTC QLQ-C30 at baseline and after each chemotherapy cycle. The prognostic significance of sex, age and WHO performance status (0-1 vs. 2) and the 15 QLQ-C30 subscales were assessed with Cox proportional hazard models stratified for treatment (level of significance 0.05). Changes in HRQoL scores from baseline to each chemotherapy cycle assessment were categorized as “improved”, “stable” and “worsened” using a threshold of 10 points difference. Due to expected attrition, the analysis was limited to changes from baseline up to cycle 3. Results: There were 248 patients in cycle 1, 212 in cycle 2 and 196 in cycle 3. We performed analyses separately using data at cycle 1, cycle 2, and cycle 3. In all analyses, HRQoL in various subscales and socio-demographic and clinical variables (physical functioning (hazard ratio [HR] 0.91, 95% CI 0.85-0.98; p=0.0103), pain (1.11, 1.05-1.17; p= 0.0004), age (0.98, 0.97-1.00, p=0.0413) and WHO performance status (1.77, 1.09-2.89; p=0.0218) at cycle 1; pain (1.11, 1.03-1.20; p=0.0016), age (0.98, 0.96-1.00; p=0.0217) and sex (0.63, 0.42-0.95; p=0.0081) at cycle 2; and role functioning (0.93, 0.88-1.00; p=0.0128) and age (0.98, 0.96-1.00; p=0.0081) at cycle 3) predicted survival; however, change in HRQoL was only an independent predictor for improvement at cycle 1. Conclusions: Our findings suggest that change from baseline over time in HRQoL, as measured on subscales of the EORTC QLQ-C30, contains added prognostic value for survival independent of baseline HRQoL scores. Further work is needed to assess the robustness and sensitivity of these findings.

scholarly journals Assessment of Quality of Life in Advanced Non-Small Cell Lung Cancer Patients on Platinum-Based Chemotherapy Combinations

QJM ◽  
2020 ◽  
Vol 113 (Supplement_1) ◽  
Author(s):  
S A Abdelwahab ◽  
A S Tawfik ◽  
N A Mosalam ◽  
E M E Ghazy
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Advanced Nsclc ◽  
Response To Treatment ◽  
Health Related Quality ◽  
Platinum Based Chemotherapy ◽  
Related Quality ◽  
Health Related ◽  
Eortc Qlq

Abstract Background Lung cancer is the most commonly diagnosed cancer worldwide for both sexes. There are 1.8 million new cases in 2012 (12.9% of the total), 58% of which occurred in the less developed regions. The disease remains the most common cancer in men worldwide (1.2 million, 16.7% of the total) and the most common causes of cancer deaths worldwide for both sexes, estimated to be responsible for nearly one in five (1.59 million deaths, 19.4% of the total) Aim of the Work are to evaluate the effect of platinum-based chemotherapy combinations as a first line treatment on health related quality of life (HRQOL) in advanced NSCLC Egyptian patients and to assess tumor’s response to treatment and treatment toxicity. Patients and Methods A prospective, single arm clinical study, to evaluate the effect of palliative chemotherapy on advanced NSCLC patient’s health related quality of life before starting chemotherapy and after 3 cycles of treatment, patient’s response to treatment and toxicity related to treatment. Results 61 patients completed the EORTC QLQ-C30 and the QLQ-LC13 for the evaluation of HRQoL before the 1st cycle of chemotherapy. Started with 70 patients, 9 were excluded during the study (because of a change in the chemotherapy protocol or because of treatment discontinuation during the following cycles of chemotherapy. Conclusion The present study explored self-reported quality of life in advanced NSCLC patients receiving chemotherapy, Aiming for a better understanding of how chemotherapy influences HRQoL. The importance of patient perception of their own health regarding the complexity of cancer, which is a disease that affects every dimension of life and the way in which individuals perceive the environment, the diagnosis, and the therapy. Therefore, the combination of periodic quality of life assessments and clinical practice should be more extensively.

Validation of the Mexican Spanish Version of the EORTC C30 and STO22 Questionnaires for the Evaluation of Health-Related Quality of Life in Patients with Gastric Cancer

2009 ◽  
Vol 16 (1) ◽  
pp. 88-95 ◽  
Author(s):  
Luis F. Oñate-Ocaña ◽  
Alberto Alcántara-Pilar ◽  
Diana Vilar-Compte ◽  
Gabriela García-Hubard ◽  
Edith Rojas-Castillo ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Gastric Cancer ◽  
Spanish Version ◽  
Health Related Quality ◽  
Mexican Spanish ◽  
Related Quality ◽  
Health Related

The effects of tislelizumab treatment on the health-related quality of life of non-small cell lung cancer patients who progressed on a prior platinum-containing regimen.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 9069-9069
Author(s):  
Cai Zhou ◽  
Dingzhi Huang ◽  
Yiyuan Ma ◽  
Zhenyu Pan ◽  
Gisoo Barnes ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Small Cell ◽  
Health Related Quality ◽  
Small Cell Lung ◽  
Related Quality ◽  
Health Related ◽  
Eortc Qlq ◽  
Nsclc Patients

9069 Background: Anti-PD-1/L1 therapies have improved overall survival (OS) by 2-4 months vs docetaxel in patients with advanced non−small cell lung cancer (NSCLC) who progressed after receiving a platinum regimen. Tislelizumab, an anti-PD-1 antibody, has been tested as monotherapy in the RATONALE (NCT 03358875) trial, which found that tislelizumab prolonged OS (median OS difference 5.3 months in ITT population) as compared to docetaxel, improved progression-free survival (median 4.1 vs 2.6 months), as well as overall response rate (ORR difference = 14.9%).Here we report health-related quality of life (HRQoL) of patients receiving tislelizumab vs docetaxel in this clinical trial. Methods: NSCLC patients in this open-label, multicenter Phase 3 study were randomized to either the tislelizumab or docetaxel. HRQoL was measured using the QLQ-C30 global health status/quality of life score (GHS/QoL) from EORTC QLQ-C30 as well as the lung cancer specific subscales of the EORTC QLQ-LC13. Descriptive analysis for the GHS/QoL score was performed for baseline through cycle 10; changes from baseline to cycle 12 were examined for the symptom subscales. Results: 805 patients were randomized to tislelizumab (n = 535) or docetaxel (n = 270). Patients were 77% male with an average age of 60 years (range 28-88 years). The compliance rates were mostly > 98% and were similar across arms. The GHS/QoL score in the tislelizumab arm improved relative to baseline from cycles 5 through 10 while declining in cycles 6 through 10 in the docetaxel arm. The tislelizumab arm showed a reduction from baseline at cycle 12 in the symptom scores of coughing, chest pain, and dyspnea while patients in the docetaxel arm experienced an increase in symptoms. Conclusions: The study results show that tislelizumab monotherapy improved HRQoL in patients who previously failed treatment with a platinum containing chemotherapy; this is especially important as the NSCLC patients treated with tislelizumab not only experienced improvements in OS, but also reductions in their symptomology. Clinical trial information: NCT 03358875.

Validation of the Mexican-Spanish version of the EORTC QLQ-C15-PAL questionnaire for the evaluation of health-related quality of life in patients on palliative care

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e20557-e20557
Author(s):  
L. F. Onate-Ocana ◽  
Y. Suárez-del-Real ◽  
S. Allende-Pérez ◽  
A. Alférez-Mancera ◽  
R. B. Rodríguez ◽  
...  
Keyword(s):  
Palliative Care ◽  
Spanish Version ◽  
Health Related Quality ◽  
Mexican Spanish ◽  
Patients With Cancer ◽  
Scale Scores ◽  
Related Quality ◽  
Health Related ◽  
Eortc Qlq

e20557 Background: Health-related quality of life (HRQL) is a fundamental outcome in oncology and this is particularly important in the palliative care setting. Our aim was to validate the Mexican-Spanish version of the EORTC QLQ-C15-PAL questionnaire, which is a brief version of QLQ-C30, for the measure of HRQL in terminal patients with cancer. Methods: Patients attending the Palliative Care Unit at the Hospital from July to October 2008 with terminal cancer, diagnosed by biopsy and without any active anti-neoplasic treatment were included in this study. Mexican-Spanish version of the EORTC QLQ-C15-PAL questionnaire was used to measure HRQL. Linear transformation of scale scores were done after EORTC guidelines. Correlation analysis was done obtaining the Spearman correlation coefficient and the Cochran alpha. Association of clinical parameters and scale scores were analyzed using one-way ANOVA and Chi-squared test. Test-retest comparison was tested using ANOVA for repeated measurements. Survival analysis was performed using the Kaplan-Meier and Cox's methods. Results: Eighty-three patients were enrolled in this study (mean age of 61.2 years). Compliance rates were high; all patients answered the questionnaire in less than 20 minutes and it was well-accepted. Five missing values in five different items were found. Scales in the QLQ-C15 distinguished between other clinically distinct groups of patients. Multi-trait scaling analysis demonstrated good convergent and discriminant validity. Cronbach's alpha coefficients were >0.7 in three of four multi-item scales. Test-retest scores were obtained from 25 patients and scores were consistent. Emotional function, Dyspnea, Insomnia and Appetite scales demonstrated an important association with overall survival by multivariate analysis (p<0.05). Conclusions: The Mexican-Spanish version of EORTC QLQ-C15-PAL questionnaire is reliable and valid for HRQL measurement in terminal patients with cancer, and appropriate for its use in clinical trials in Mexican patients. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document